A primary engine of growth and innovation within the US contract research sector is the burgeoning landscape of Emerging Biopharma (EBP) companies. These smaller, often pre-commercial firms are responsible for a significant percentage of new drug candidates entering clinical trials, particularly those focused on novel, complex modalities and niche therapeutic areas. Unlike large pharmaceutical...